

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Auerbach et al.

Serial No.: Not Yet Known **Group:** Not Yet Assigned

Filing Date: Filed Herewith **Examiner:** Not Yet Assigned

Title: Method of Improving Gene Targeting Using A Ubiquitin Promoter

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56 and 1.97**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450


Dear Sir:

In compliance with the applicant's duty to submit information material to patentability of the above-referenced case, Applicants herein submit the following Information Disclosure Statement with the accompanying PTO Form. The PTO is kindly requested to make of record those references which may be pertinent to the examination of the above-referenced application.

This Information Disclosure Statement is being filed:

Within three months of the filing date of the above referenced application; within three months of the entry of an international application into the national phase; before the mailing date of a first Office action on the merits; or before the mailing of a first Office action after the filing of a request for continued examination under § 1.114. Accordingly, no fee is required for the submission.

Respectfully submitted


Valeta Gregg
Reg. No. 35,127
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Att. Docket No. : REG 784
Serial No. : to be assigned
Applicant: : Auerbach, et al.
Date Filed : Concurrently herewith
For : METHOD OF IMPROVING GENE
TARGETING USING A UBIQUITIN
PROMOTER

Examiner : Not Yet Known
Group Art Unit : Not Yet Known

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

U.S. PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Patent Number</u>	<u>Patent Date</u>	<u>Name</u>	<u>Class/Subclass</u>	<u>Filing Date</u>
--------------------------	----------------------	--------------------	-------------	-----------------------	--------------------

FOREIGN PATENT DOCUMENTS

<u>Examiner Initials</u>	<u>Document Number</u>	<u>Date</u>	<u>Country</u>	<u>Class/Subclass</u>	<u>Translation Yes</u>	<u>No</u>
--------------------------	------------------------	-------------	----------------	-----------------------	------------------------	-----------

OTHER DOCUMENTS

**Examiner
Initials**

NUCLEIC ACIDS RESEARCH, Vol. 24, 1996, Schorpp, M., et al. "The human ubiquitin C promoter directs high ubiquitous expression of transgenes in mice" pp. 1787-1788.


EXAMINER
CONSIDERED

DATE

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Respectfully submitted,

By:



Valeta Gregg
Reg. No. 35,127
Attorneys for Applicant
Patent Agent for Applicant
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
Tarrytown, New York 10591
(914) 345-7400